Combining rapid diagnostic tests to estimate primary and post-primary dengue immune status at the point of care

Background Characterising dengue virus (DENV) infection history at the point of care is challenging as it relies on intensive laboratory techniques. We investigated how combining different rapid diagnostic tests (RDTs) can be used to accurately determine the primary and post-primary DENV immune status of reporting patients during diagnosis. Methods and findings Serum from cross-sectional surveys of acute suspected dengue patients in Indonesia (N:200) and Vietnam (N: 1,217) were assayed using dengue laboratory assays and RDTs. Using logistic regression modelling, we determined the probability of being DENV NS1, IgM and IgG RDT positive according to corresponding laboratory viremia, IgM and IgG ELISA metrics. Laboratory test thresholds for RDT positivity/negativity were calculated using Youden’s J index and were utilized to estimate the RDT outcomes in patients from the Philippines, where only data for viremia, IgM and IgG were available (N:28,326). Lastly, the probabilities of being primary or post-primary according to every outcome using all RDTs, by day of fever, were calculated. Combining NS1, IgM and IgG RDTs captured 94.6% (52/55) and 95.4% (104/109) of laboratory-confirmed primary and post-primary DENV cases, respectively, during the first 5 days of fever. Laboratory test predicted, and actual, RDT outcomes had high agreement (79.5% (159/200)). Among patients from the Philippines, different combinations of estimated RDT outcomes were indicative of post-primary and primary immune status. Overall, IgG RDT positive results were confirmatory of post-primary infections. In contrast, IgG RDT negative results were suggestive of both primary and post-primary infections on days 1–2 of fever, yet were confirmatory of primary infections on days 3–5 of fever. Conclusion We demonstrate how the primary and post-primary DENV immune status of reporting patients can be estimated at the point of care by combining NS1, IgM and IgG RDTs and considering the days since symptoms onset. This framework has the potential to strengthen surveillance operations and dengue prognosis, particularly in low resource settings.

[1]  O. Brady,et al.  Estimating the annual dengue force of infection from the age of reporting primary infections across urban centres in endemic countries , 2021, BMC Medicine.

[2]  O. Brady,et al.  Serological Evidence of Widespread Zika Transmission across the Philippines , 2021, Viruses.

[3]  L. Ng,et al.  Rapid diagnostic tests for the detection of recent dengue infections: An evaluation of six kits on clinical specimens , 2021, PloS one.

[4]  O. Brady,et al.  A serological framework to investigate acute primary and post-primary dengue cases reporting across the Philippines , 2020, BMC Medicine.

[5]  R. Peeling,et al.  Optimising dengue pre-vaccination screening , 2020, The Lancet Infectious Diseases.

[6]  R. Shukla,et al.  Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine , 2020, Frontiers in Cellular and Infection Microbiology.

[7]  Chun-Hong Chen,et al.  Evaluation of rapid diagnostic tests to detect dengue virus infections in Taiwan , 2020, PloS one.

[8]  M. Halloran,et al.  Zika virus infection enhances future risk of severe dengue disease , 2020, Science.

[9]  G. Ippolito,et al.  Performance of rapid tests in the management of dengue fever imported cases in Lazio, Italy 2014-2019. , 2020, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[10]  M. Hibberd,et al.  Diagnostic accuracy of 5 different brands of dengue virus non-structural protein 1 (NS1) antigen rapid diagnostic tests (RDT) in Indonesia. , 2020, Diagnostic microbiology and infectious disease.

[11]  S. Sekaran,et al.  Diagnostic accuracy and utility of three dengue diagnostic tests for the diagnosis of acute dengue infection in Malaysia , 2020, BMC Infectious Diseases.

[12]  D. Cummings,et al.  Mapping global variation in dengue transmission intensity , 2020, Science Translational Medicine.

[13]  Peter G. Smith,et al.  Vaccine-attributable severe dengue in the Philippines , 2019, The Lancet.

[14]  Stephen J. Thomas,et al.  A review of Dengvaxia®: development to deployment , 2019, Human vaccines & immunotherapeutics.

[15]  R. Maude,et al.  A review of dengue diagnostics and implications for surveillance and control , 2019, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[16]  S. Hasan,et al.  Zika Virus: A Global Public Health Menace: A Comprehensive Update , 2019, Journal of International Society of Preventive & Community Dentistry.

[17]  R. Peeling,et al.  Rapid diagnostic tests for determining dengue serostatus: a systematic review and key informant interviews , 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[18]  D. Cummings,et al.  Long-term circulation of Zika virus in Thailand: an observational study. , 2019, The Lancet. Infectious diseases.

[19]  C. Lim,et al.  Comparative evaluation of three dengue duo rapid test kits to detect NS1, IgM, and IgG associated with acute dengue in children in Myanmar , 2019, PloS one.

[20]  M. Reis,et al.  Accuracy of the SD BIOLINE Dengue Duo for rapid point-of-care diagnosis of dengue , 2019, PloS one.

[21]  A. S. St. John,et al.  Adaptive immune responses to primary and secondary dengue virus infections , 2019, Nature Reviews Immunology.

[22]  T. Madani,et al.  Assessment of the new World Health Organization's dengue classification for predicting severity of illness and level of healthcare required , 2019, bioRxiv.

[23]  I. Dorigatti,et al.  Spatiotemporal variability in dengue transmission intensity in Jakarta, Indonesia , 2018, bioRxiv.

[24]  G. Chang,et al.  Comprehensive Evaluation of Differential Serodiagnosis between Zika and Dengue Viral Infections , 2018, Journal of Clinical Microbiology.

[25]  C. Simmons,et al.  Methods to discriminate primary from secondary dengue during acute symptomatic infection , 2018, BMC Infectious Diseases.

[26]  T. Westling,et al.  Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy , 2018, The New England journal of medicine.

[27]  M. Halloran,et al.  Antibody-dependent enhancement of severe dengue disease in humans , 2017, Science.

[28]  D. Gubler,et al.  Chymase Level Is a Predictive Biomarker of Dengue Hemorrhagic Fever in Pediatric and Adult Patients , 2017, The Journal of infectious diseases.

[29]  C. Pannuti,et al.  Cross reactivity of commercial anti‐dengue immunoassays in patients with acute Zika virus infection , 2017, Journal of medical virology.

[30]  T. Mir,et al.  Differentiating secondary from primary dengue using IgG to IgM ratio in early dengue: an observational hospital based clinico-serological study from North India , 2016, BMC Infectious Diseases.

[31]  Mario Recker,et al.  The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study , 2016, PLoS medicine.

[32]  H. Margolis,et al.  Performance of Dengue Diagnostic Tests in a Single-Specimen Diagnostic Algorithm. , 2016, The Journal of infectious diseases.

[33]  Uma S. Kamaraj,et al.  Extended Evaluation of Virological, Immunological and Pharmacokinetic Endpoints of CELADEN: A Randomized, Placebo-Controlled Trial of Celgosivir in Dengue Fever Patients , 2016, PLoS neglected tropical diseases.

[34]  M. Chen,et al.  Discovery and Validation of Prognostic Biomarker Models to Guide Triage among Adult Dengue Patients at Early Infection , 2016, PloS one.

[35]  O. Horstick,et al.  Dengue , 2015, The Lancet.

[36]  A. Kurniawan,et al.  Immunoglobulin G (IgG) to IgM ratio in secondary adult dengue infection using samples from early days of symptoms onset , 2015, BMC Infectious Diseases.

[37]  Katia Koelle,et al.  Minimal within-host dengue models highlight the specific roles of the immune response in primary and secondary dengue infections , 2015, Journal of The Royal Society Interface.

[38]  S. Halstead Dengue Antibody-Dependent Enhancement: Knowns and Unknowns. , 2014, Microbiology spectrum.

[39]  G. Ogg,et al.  Dengue NS1 antigen as a marker of severe clinical disease , 2014, BMC Infectious Diseases.

[40]  John S. Brownstein,et al.  The global distribution and burden of dengue , 2013, Nature.

[41]  N. Lennon,et al.  Dynamics of Dengue Disease Severity Determined by the Interplay Between Viral Genetics and Serotype-Specific Immunity , 2011, Science Translational Medicine.

[42]  Cameron P. Simmons,et al.  Kinetics of Viremia and NS1 Antigenemia Are Shaped by Immune Status and Virus Serotype in Adults with Dengue , 2011, PLoS neglected tropical diseases.

[43]  Rosanna W. Peeling,et al.  Evaluation of Commercially Available Anti–Dengue Virus Immunoglobulin M Tests , 2009, Emerging infectious diseases.

[44]  N. M. Dung,et al.  Patterns of gene transcript abundance in the blood of children with severe or uncomplicated dengue highlight differences in disease evolution and host response to dengue virus infection. , 2009, The Journal of infectious diseases.

[45]  Mark J. Schreiber,et al.  Decision Tree Algorithms Predict the Diagnosis and Outcome of Dengue Fever in the Early Phase of Illness , 2008, PLoS neglected tropical diseases.

[46]  R. Lanciotti,et al.  Serotype-Specific Detection of Dengue Viruses in a Fourplex Real-Time Reverse Transcriptase PCR Assay , 2005, Journal of Clinical Microbiology.

[47]  J. Low,et al.  Prognosticating Dengue. , 2017, Clinical Infectious Diseases.

[48]  S. Halstead,et al.  Dengue infection , 2016, Nature Reviews Disease Primers.

[49]  L. Gomes,et al.  Author ' s response to reviews Title : Dengue NS 1 antigen as a marker of severe clinical disease , 2014 .

[50]  A. Nisalak,et al.  Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. , 2000, The Journal of infectious diseases.

[51]  G. Crane Dengue haemorrhagic fever: diagnosis, treatment, prevention and control , 1999 .

[52]  Z. Sagan [Laboratory diagnosis]. , 1971, Pielegniarka i polozna.

[53]  W. Youden,et al.  Index for rating diagnostic tests , 1950, Cancer.